RxDoctor Payments Data

John Thayer, MD

Ophthalmology · Westfield, MANPI 1386628279

Payments from drug & device makers

$460in general payments, 2019–2025

Across 19 payments — averaging $24.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$127
  • Alcon$114
  • Ocular Therapeutix, Inc.$67
  • Bausch & Lomb Americas Inc.$62
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$39
  • Aerie Pharmaceuticals, Inc.$36
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$460100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$460 in reported general payments places this provider in the 40th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$427,076
Medicare patients
1,044
Services billed
3,589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine60$51,079
ProlensaBromfenac Sodium97$34,091
RocklatanNetarsudil Mesylat/Latanoprost60$28,240
Bromfenac Sodium126$24,425
VyzultaLatanoprostene Bunod43$17,666
CombiganBrimonidine Tartrate/Timolol60$16,346
SimbrinzaBrinzolamide/Brimonidine Tart64$15,323
LumiganBimatoprost41$14,497
Loteprednol Etabonate69$12,330
Brimonidine Tartrate162$10,241
RhopressaNetarsudil Mesylate19$9,852
Methazolamide20$6,179
MoxifloxacinMoxifloxacin Hcl327$6,173
Lotemax SmLoteprednol Etabonate16$4,047
Latanoprost257$2,881

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$127$81,922161 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax Sm$39$50,468182 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$36$38,09279 claims
Bausch & Lomb Americas Inc.Vyzulta$62$17,66643 claims
AlconSimbrinza$114$15,32364 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Westfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →